1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsSupports expansion and sustainability of biomedical research centers; open to nonprofit organizations.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Nonprofit organizations. Confirm the full requirements in the official notice before applying.
Applications for Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed) are due May 25, 2029. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Centers of Biomedical Research Excellence: Expansion/Sustainability Phases (COBRE-E/S) (P30 - Clinical Trial Not Allowed) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Past winners and funding trends for this program
NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), Centers for Disease Control (CDC), and Food and Drug Administration (FDA). This program provides non-dilutive funding for early-stage research and development in biomedical and behavioral science, aligning with the missions of NIH, CDC, and FDA.
Small Business Technology Transfer (STTR) Program (Parent STTR [R41/R42]) is sponsored by National Institutes of Health (NIH), Department of Health and Human Services (HHS), Centers for Disease Control (CDC). This omnibus solicitation supports cooperative research and development between small businesses and non-profit research institutions to advance early-stage biomedical commercialization. It is designed to foster technology transfer.
Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This program provides additional funding for small businesses that have successfully completed Phase II SBIR projects and require extraordinary time and effort in the R&D phase to reach the marketplace. It focuses on biomedical technologies with public health impact.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article